Can you tell us about your presentation tomorrow?

First of all, my name is Jose Sandoval, thank you for the invitation. Here at the 2023 ASCO Highlights I'm going to talk about the presentations that were highlighted in ASCO 2023 in Chicago regarding non-Hodgkin’s lymphoma and Hodgkin lymphoma. Especially important this year is the presentation of the cooperative phase III trial of non-Hodgkin lymphoma where immunotherapy of checkpoint blockade with nivolumab plus AVD was compared versus the standard of care here in the United States that is called brentuximab plus AVD showing improvement in outcomes of the patient and especially very well tolerated. 

I’m also going to give an update on information regarding bispecific antibodies, both epcoritamab and glofitamab for the treatment of large B-cell lymphoma which both already have been approved by the FDA for the treatment of our patients.

Last, but not least, I’m going to give an update also of the role of pirtobrutinib that is a new generation BTK inhibitor for the treatment of mantle cell lymphoma. I’m going to conclude the presentation with the initial report of one of the big cooperative studies in CLL comparing two doublet treatments of a BTK inhibitor plus a monoclonal antibody versus that doublet adding venetoclax, which is a BCL2 inhibitor.

Can you highlight any specialised programs or services offered by MCI that have been developed in collaboration with Moffitt Cancer Center?

Moffitt Cancer Center created a strategic collaboration with Memorial Healthcare System and Memorial Cancer Institute since summer 2017, so it’s coming up to six years now. We created down here the Department of Malignant Haematology and Cellular Therapy of which I’m one of the associate members. Since the inception of the department we have grown the program of haematopoietic stem cell transplantation and, for the past two years or so, we brought up also the Department of Cellular Therapy, specifically chimeric antigen receptor T-cell therapy, or CAR T-cell therapy. 

Currently we are treating different types of B-cell lymphoma and also B-cell acute lymphoblastic leukaemia with commercial CAR T-cell products. All of them are available. Hopefully very soon we will also be treating patients with relapsed and refractory multiple myeloma with commercially available CAR T-cell therapy for those malignancies.